Brief: Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004
03/12/2025 13:05
Dec 3 (Reuters) - Sutro Biopharma Inc STRO.O: SUTRO BIOPHARMA ANNOUNCES FIRST COHORT OF PATIENTS DOSED IN PHASE 1 TRIAL OF STRO-004, A NEXT-GENERATION TISSUE FACTOR ADC, IN TF-EXPRESSING SOLID TUMORS SUTRO BIOPHARMA INC - INITIAL CLINICAL DATA EXPECTED MID-2026 Source text: ID:nGNX4Pq1fN Further company coverage: STRO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sutro Biopharma
See all newsBrief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma tumbles after missing estimates